Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Dimethylfumarate Impairs Neutrophil Functions.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Multiple sclerosis: pathogenesis and treatment.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Dimethyl fumarate for multiple sclerosis.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Pages